<DOC>
	<DOCNO>NCT01433445</DOCNO>
	<brief_summary>This study ass safety well establish Recommended Phase II dose combination panobinostat ruxolitinib patient without JAK2V617F mutation diagnose primary myelofibrosis ( PMF ) , Post Essential Thrombocythemia Myelofibrosis ( PET MF ) , Post-Polycythemia Vera Myelofibrosis ( PPV MF ) .</brief_summary>
	<brief_title>Panobinostat Ruxolitinib Primary Myelofibrosis , Post-polycythemia Vera-myelofibrosis Post-essential Thrombocythemia-myelofibrosis</brief_title>
	<detailed_description />
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Thrombocytosis</mesh_term>
	<mesh_term>Thrombocythemia , Essential</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<criteria>Diagnosis myelofibrosis , either PMF , PPV PET MF Palpable splenomegaly ≥ 5cm May previously treat either panobinostat ruxolitinib ( unless discontinue clinically relevant toxicity ) Acceptable lab range organ system Specifically : Platelet count &gt; 100,000 reach aide transfusion Blast count &lt; 10 % screen ECOG ≤ 2 Must able discontinue drug use treat MF least 7 day prior start study drug Active malignancy Clinically significant heart disease Splenic irradiation within 12 month start study drug Need ongoing systemic anticoagulation exception Aspirin &lt; 150mg/day Low Molecular Weight Heparin History platelet dysfunction bleed disorder 6 month prior screen Patient risk spontaneous bleed Willing and/or eligible stemcell transplantation Impairment gastrointestinal function may impact absorption study treatment Unwilling use highly effective method contraception dose 13 week ( female participant ) 6 month ( male participant female partner ) stop study treatment Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Myelofibrosis</keyword>
	<keyword>Panobinostat</keyword>
	<keyword>Ruxolitinib</keyword>
	<keyword>MF</keyword>
	<keyword>PMF</keyword>
	<keyword>PPV</keyword>
	<keyword>PPV-MF</keyword>
	<keyword>PET</keyword>
	<keyword>PET-MF</keyword>
	<keyword>JAK2</keyword>
	<keyword>DACi</keyword>
</DOC>